Header Logo

Connection

HELEN HESLOP to Animals

Back to Details
This is a "connection" page, showing publications HELEN HESLOP has written about Animals.
HELEN HESLOP
Connection Strength
0.413
Animals
  1. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016 06 30; 127(26):3331-40.
    View in: PubMed
    Score: 0.027
  2. T lymphocytes targeting native receptors. Immunol Rev. 2014 Jan; 257(1):39-55.
    View in: PubMed
    Score: 0.023
  3. Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet. 2011 Apr 15; 20(R1):R93-9.
    View in: PubMed
    Score: 0.019
  4. Safer CARS. Mol Ther. 2010 Apr; 18(4):661-2.
    View in: PubMed
    Score: 0.018
  5. Adoptive T cell therapy of cancer. Curr Opin Immunol. 2010 Apr; 22(2):251-7.
    View in: PubMed
    Score: 0.018
  6. The clone ranger? Mol Ther. 2008 Sep; 16(9):1520-1.
    View in: PubMed
    Score: 0.016
  7. Current status of genetic modification of T cells for cancer treatment. Cytotherapy. 2005; 7(3):262-72.
    View in: PubMed
    Score: 0.012
  8. Bispecific antibodies and autologous chimeric antigen receptor T?cell therapies for treatment of hematological malignancies. Mol Ther. 2024 08 07; 32(8):2444-2460.
    View in: PubMed
    Score: 0.012
  9. Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
    View in: PubMed
    Score: 0.012
  10. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
    View in: PubMed
    Score: 0.011
  11. Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.
    View in: PubMed
    Score: 0.011
  12. Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
    View in: PubMed
    Score: 0.011
  13. Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
    View in: PubMed
    Score: 0.011
  14. Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
    View in: PubMed
    Score: 0.011
  15. Immunotherapy to reconstitute immunity to DNA viruses. Semin Hematol. 2002 Jan; 39(1):41-7.
    View in: PubMed
    Score: 0.010
  16. Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
    View in: PubMed
    Score: 0.009
  17. Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
    View in: PubMed
    Score: 0.009
  18. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
    View in: PubMed
    Score: 0.007
  19. Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity. Mol Med Today. 1997 Jan; 3(1):24-30.
    View in: PubMed
    Score: 0.007
  20. Policy: Global standards for stem-cell research. Nature. 2016 05 19; 533(7603):311-3.
    View in: PubMed
    Score: 0.007
  21. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
    View in: PubMed
    Score: 0.006
  22. Gene transfer into human hemopoietic progenitor cells. Br Med Bull. 1995 Jan; 51(1):167-91.
    View in: PubMed
    Score: 0.006
  23. Survivin-specific T cell receptor targets tumor but not T cells. J Clin Invest. 2015 Jan; 125(1):157-68.
    View in: PubMed
    Score: 0.006
  24. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014 Jun 12; 123(24):3750-9.
    View in: PubMed
    Score: 0.006
  25. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
    View in: PubMed
    Score: 0.006
  26. Cytokine gene transfer in the therapy of malignancy. Baillieres Clin Haematol. 1994 Mar; 7(1):135-51.
    View in: PubMed
    Score: 0.006
  27. Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
    View in: PubMed
    Score: 0.006
  28. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
    View in: PubMed
    Score: 0.006
  29. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013 Oct; 174(1):89-96.
    View in: PubMed
    Score: 0.006
  30. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013 Nov; 21(11):2087-101.
    View in: PubMed
    Score: 0.006
  31. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica. 2013 Apr; 98(4):533-7.
    View in: PubMed
    Score: 0.005
  32. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012 Feb; 20(2):246-9.
    View in: PubMed
    Score: 0.005
  33. Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7.
    View in: PubMed
    Score: 0.005
  34. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One. 2011; 6(5):e20267.
    View in: PubMed
    Score: 0.005
  35. An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15.
    View in: PubMed
    Score: 0.005
  36. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
    View in: PubMed
    Score: 0.004
  37. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010 Jan 15; 16(2):474-85.
    View in: PubMed
    Score: 0.004
  38. Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
    View in: PubMed
    Score: 0.004
  39. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009 Oct; 17(10):1779-87.
    View in: PubMed
    Score: 0.004
  40. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
    View in: PubMed
    Score: 0.004
  41. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8.
    View in: PubMed
    Score: 0.004
  42. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5.
    View in: PubMed
    Score: 0.004
  43. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
    View in: PubMed
    Score: 0.004
  44. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007 Jun 15; 67(12):5957-64.
    View in: PubMed
    Score: 0.004
  45. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
    View in: PubMed
    Score: 0.004
  46. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
    View in: PubMed
    Score: 0.003
  47. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60.
    View in: PubMed
    Score: 0.003
  48. T cell therapies. Ernst Schering Found Symp Proc. 2006; (4):69-82.
    View in: PubMed
    Score: 0.003
  49. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54.
    View in: PubMed
    Score: 0.003
  50. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8.
    View in: PubMed
    Score: 0.003
  51. Gene-marking studies of hematopoietic cells. Int J Hematol. 2001 Jan; 73(1):14-22.
    View in: PubMed
    Score: 0.002
  52. Allogeneic red blood cells fail to induce haemagglutinating antibodies or cellular alloimmunity in rats and are immunosuppressive. Transplantation. 1979 Aug; 28(2):144-8.
    View in: PubMed
    Score: 0.002
  53. A method for preparing leucocyte depleted erythrocytes from rat blood. J Immunol Methods. 1978; 22(3-4):389-91.
    View in: PubMed
    Score: 0.002
  54. IL-2 infusion abrogates humoral immune responses in humans. Clin Exp Immunol. 1992 Mar; 87(3):493-8.
    View in: PubMed
    Score: 0.001
  55. Loss of the amino-terminal helix-loop-helix domain of the vav proto-oncogene activates its transforming potential. Mol Cell Biol. 1991 Apr; 11(4):1912-20.
    View in: PubMed
    Score: 0.001
  56. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood. 1989 Apr; 73(5):1351-8.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.